Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)

This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may begin in the hospital and will continue following release from the hospital or may begin following release from hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (up to12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

Start Date03 Oct 2023

Sponsor / Collaborator

DalCor Pharmaceuticals Canada, Inc.

NCT04676867

/ CompletedPhase 2

A Double-blind, Placebo-controlled, Phase 2a Proof-of-concept Trial of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.

Start Date11 Jan 2021

Sponsor / Collaborator

DalCor Pharmaceuticals Canada, Inc.

[+1]

NCT02525939

/ CompletedPhase 3

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in the hospital and will continue following release from the hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (4-12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

Start Date01 Apr 2016

Sponsor / Collaborator

DalCor Pharmaceuticals Canada, Inc.

[+2]

100 Clinical Results associated with Dalcetrapib

100 Translational Medicine associated with Dalcetrapib

100 Patents (Medical) associated with Dalcetrapib

294

Literatures (Medical) associated with Dalcetrapib

01 Nov 2024·Journal of Computational Biophysics and Chemistry

Molecular Docking, Quantum Mechanics and Molecular Dynamics Simulation of Anti-CAD Drugs Against High-Risk Xanthine Dehydrogenase Variants Associated with Oxidative Stress Pathways

Author: Ahmed, Shiek S. S. J. ; Sudhan, M. ; Emran, Talha Bin ; Attia, Sabry M. ; Ahmad, Sheikh F. ; Janakiraman, V.

Xanthine dehydrogenase (XDH) contributes significantly to generating reactive oxygen species in coronary artery disease (CAD). XDH has been proposed as a therapeutic target, but its genetic variants could affect protein structure and drug response. We aimed to assess protein structure modification occur due to genetic variants and to screen 215 CAD drugs for their utility in personalized CAD treatment against the XDH variants. A series of computational methods were implemented to identify pathogenic variants that cause XDH structure instability localized at the con served regions contributing to functional significance. Then, the XDH structures with the pathogenic variants were modeled using two different approaches to select the best models for docking with the CAD drugs. Finally, the stability of the docked complexes and their ability to transfer electrons were evaluated using molecular dynamics (MD) simulations and quantum mechanics/molecular mechanics (QM/MM) calculation. Among 751 variants examined; R149C and Q919R showed high pathogenicity, localized in conserved regions could alter protein structure and function. Further, docking of CAD drugs against XDH (native, R149C and Q919R) showed vericiguat with higher affinity, ranging from −7.95 kcal/mol to −10.41 kcal/mol, than the well-known XDH inhibitor (febuxostat, −5.73 kcal/mol to −8.35 kcal/mol). This indicates that vericiguat will be effective in CAD treatment, regardless of the XDH variants. Additionally, MD simulation and QM/MM confirmed vericiguat stability and electron transfer ability to form hydrogen bonds with the XDH protein. In conclusion, vericiguat will be beneficial for the personalized treatment of CAD by inhibiting XDH variants. Additional clinical studies are necessary to confirm our findings.

01 Jun 2024·JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Enhancing HDL Function to Prevent Atherothrombosis

Author: Finn, Aloke V

THis study is about Enhancing HDL Function to Prevent Atherothrombosis.Despite advances in our understanding of the pathogenesis of acute myocardial infarction (MI), atherosclerotic coronary artery disease remains a leading cause of death in the world.Here it was discussed about the deposition of cholesterol in the form of lipoproteins within the walls of blood vessels leads to the development of atherosclerotic plaques.Death and morbidity from atherosclerotic heart disease have been diminishing largely because of better risk factor management including control of low-d. lipoprotein cholesterol(LDL-C) levels.However,patients with established atherosclerotic cardiovascular (CV) disease are at very high risk for recurrent events, including MI, stroke,and death even on LDL-C lowering therapies.Epidemiol. studies have shown a strong inverse correlation between circulating high-d. lipoprotein (HDL) cholesterol and the risk of ischemic heart disease.The main function of HDL is to scavenge excess cholesterol from peripheral tissues back to the liver through a process called reverse cholesterol transport.However, the development of new therapies that increase plasma HDL levels has proven challenging, highlighted by the failure of torc etrapib and dalcetrapib, 2 different inhibitors of cholesteryl ester transfer protein, and of extended release niacin in recent clin. trials.Last, would CSL112 be more effective in the early stages of atherosclerosis where plaque necrosis is less advanced (pathol. intimal thickening and early fibroatheroma) and lipid particle (oxidized LDL) are attached to proteoglycan hyaluronan and versican.Whereas treating patients with late-stage disease remains an important and worthy goal, enhancing cholesterol efflux at the earliest stages of disease in those with known impaired function may have a larger effect on plaque growth and progression.To date the field is littered with mostly failed trials to improve CV outcomes in patients treated with guideline driven LDL-lowering therapies..Nonetheless, agents with different mechanisms for preventing atherothrombosis beyond LDL-C lowering are needed to further reduce cardiovascular events.This biol. underpinning behind HDL-enhancing therapies is sound but further work is needed to explore any potential benefits.

05 Dec 2023·Journal of the American Heart Association

Interventions to Attenuate Cardiovascular Calcification Progression: A Systematic Review of Randomized Clinical Trials

Review

Author: Toussaint, Nigel D. ; Murali, Shashank ; Smith, Edward R. ; Tan, Sven‐Jean ; Tiong, Mark K.

Background:

Cardiovascular calcification, characterized by deposition of calcium phosphate in the arterial wall and heart valves, is associated with cardiovascular morbidity and mortality and is commonly seen in aging, diabetes, and chronic kidney disease. Whether evidence‐based interventions could significantly attenuate cardiovascular calcification progression remains uncertain.

Methods and Results:

We conducted a systematic review of randomized controlled trials involving interventions, compared with placebo, another comparator, or standard of care, to attenuate cardiovascular calcification. Included clinical trials involved participants without chronic kidney disease, and the outcome was cardiovascular calcification measured using radiological methods. Quality of evidence was determined by the Cochrane risk of bias and Grading of Recommendations, Assessment, Development, and Evaluations assessment. Forty‐nine randomized controlled trials involving 9901 participants (median participants 104, median duration 12 months) were eligible for inclusion. Trials involving aged garlic extract (n=6 studies) consistently showed attenuation of cardiovascular calcification. Trials involving 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors (n=14), other lipid‐lowering agents (n=2), hormone replacement therapies (n=3), vitamin K (n=5), lifestyle measures (n=4), and omega‐3 fatty acids (n=2) consistently showed no attenuation of cardiovascular calcification with these therapies. Trials involving antiresorptive (n=2), antihypertensive (n=2), antithrombotic (n=4), and hypoglycemic agents (n=3) showed mixed results. Singleton studies involving salsalate, folate with vitamin B6 and 12, and dalcetrapib showed no attenuation of cardiovascular calcification. Overall, Cochrane risk of bias was moderate, and the Grading of Recommendations, Assessment, Development, and Evaluations assessment for a majority of analyses was moderate certainty of evidence.

Conclusions:

Currently, there are insufficient or conflicting data for interventions evaluated in clinical trials for mitigation of cardiovascular calcification. Therapy involving aged garlic extract appears most promising, but evaluable studies were small and of short duration.

News (Medical) associated with Dalcetrapib

17 Nov 2023

·synapse.patsnap.com

What are CETP inhibitors and how do you quickly get the latest development progress?

CETP, or Cholesteryl Ester Transfer Protein, plays a crucial role in lipid metabolism within the human body. It facilitates the transfer of cholesteryl esters (CE) and triglycerides (TG) between high-density lipoproteins (HDL) and low-density lipoproteins (LDL). By promoting the exchange of lipids, CETP contributes to the redistribution of cholesterol and triglycerides among lipoprotein particles. This process is essential for maintaining a healthy lipid profile and preventing the accumulation of cholesterol in the arteries. Understanding the function of CETP has led to the development of pharmaceutical interventions aimed at modulating its activity to improve cardiovascular health. Currently, the main drugs for increasing HDL-C include fibrates, niacin, and Cholesteryl Ester Transfer Protein (CETP) inhibitors. Among them, CETP inhibitors are the most potent in elevating HDL-C levels, making them a recent focus of major pharmaceutical companies. CETP is a plasma glycoprotein synthesized by the liver, most of which circulates in combination with HDL. The primary function of CETP is to mediate the transfer of cholesterol from HDL to VLDL and LDL during the process of triacylglycerol exchange, and CETP inhibitors can block this transfer process, theoretically possessing anti-atherosclerosis effects and the ability to reduce cardiovascular risks. The first CETP inhibitor developed by Pfizer in 2006, Torcetrapib, significantly increased HDL-C in coronary disease patients by 72.1%, but paradoxically, this increase led to a rise in cardiovascular events and mortality risk. In 2012, Dalcetrapib, a CETP inhibitor developed by Roche, significantly increased HDL-C levels by 31% to 40% compared to baseline in acute coronary syndrome patients during the dal-OUTCOMES phase III trial with an average follow-up of 31 months. However, the benefits in the primary endpoint (a composite of coronary death, nonfatal myocardial infarction, ischemic stroke, unstable angina, or cardiac arrest revival) were no better than the placebo group, and its development was also terminated. Lilly ceased development of its CETP inhibitor evacetrapib on October 12, 2015, and the prospects for Merck's anacetrapib are similarly bleak. However, research and development of CETP inhibitors have not stopped, with drugs such as BAY60-5521, JNJ-28545595, TA8895, and CKD519 gradually entering the preclinical development phase. Recent studies regarding the safety, tolerability, and pharmacodynamics of CKD-519 in a single ascending dose study with 40 healthy volunteers demonstrated that a single dose of CKD-519 (25 mg to 400 mg) significantly increased HDL-C levels without causing severe adverse events, nor causing an increase in blood pressure similar to that caused by Torcetrapib. Therefore, the issue that increasing HDL-C does not decrease cardiovascular events and mortality risk, as well as the future research direction for CETP inhibitors, have become recent points of discussion and research focus. How do they work?CETP inhibitors are a type of drug that target the cholesteryl ester transfer protein (CETP). CETP is a protein involved in the transfer of cholesterol esters between lipoproteins, such as high-density lipoprotein (HDL) and low-density lipoprotein (LDL). From a biomedical perspective, CETP inhibitors are designed to block the activity of CETP, thereby increasing the levels of HDL cholesterol and reducing the levels of LDL cholesterol. This mechanism is based on the understanding that higher levels of HDL cholesterol are associated with a lower risk of cardiovascular diseases, while elevated levels of LDL cholesterol are linked to an increased risk. By inhibiting CETP, these drugs aim to promote a favorable lipid profile and potentially reduce the risk of conditions like atherosclerosis, heart attacks, and strokes. However, it is important to note that the clinical efficacy and safety of CETP inhibitors are still being evaluated, and more research is needed to fully understand their potential benefits and risks. List of CETP InhibitorsThe currently marketed CETP inhibitors include: Ezetimibe/Pitavastatin CalciumDalcetrapibEvacetrapibObicetrapibObicetrapib/EzetimibeDRL-17822IcosabutateNST-1024CKD-508AnacetrapibFor more information, please click on the image below. What are CETP inhibitors used for?CETP inhibitors are approved indications include Hypercholesterolemia and Hyperlipoproteinemia Type II. For more information, please click on the image below to log in and search. How to obtain the latest development progress of CETP inhibitors?In the Synapse database, you can keep abreast of the latest research and development advances of CETP inhibitors anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

13 Sep 2023

·www.globenewswire.com

DalCor Pharmaceuticals announces Dal-GenE-2 confirmatory trial and closing of Series D financing round

MONTREAL, Sept. 13, 2023 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals today announced the closing of the company’s Series D financing round of $80m USD to conduct the Dal-GenE-2 confirmatory trial in North America under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). Dal-GenE-2 (Dal-302), a phase III, double-blind, randomized placebo-controlled study, will evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction (MI) in approximately 2,000 patients with a documented recent acute coronary syndrome (ACS) and the AA genotype at variant rs1967309 in the ADCY9 gene. “Following the dal-GenE trial results showing a potential benefit in a genetically defined patient population, we are pleased to have reached agreement with the FDA to conduct the Dal-GenE-2 confirmatory trial to support a potential new drug application (NDA) filing,” said Dr. Fouzia Laghrissi Thode, CEO of DalCor Pharmaceuticals. This confirmatory trial follows the results of the dal-GenE trial which showed a 21% relative risk reduction (RRR) in fatal and non-fatal MI in 6,149 patients across 34 countries, and a 45% RRR in 1,200 patients in North America and confirmed the safety profile of dalcetrapib. “The AA genotype frequency is up to 20% in European populations and is higher than 40% in populations of African ancestery,” said Dr Eldrin F. Lewis, Chief of the Division of Cardiovascular Medicine at Stanford University, Professor of Cardiovascular Medicine, and Chair of the Dal-GenE-2 diversity committee. “With the relative risk reduction seen in North American patients in the dal-GenE study and the continued commitment to investigating the first potential pharmacogenetic precision medicine for patients with cardiovascular disease, we are pleased to partner with DalCor Pharmaceuticals in this confirmatory trial.” The Series D financing includes the participation of Fonds de Developpement Économique from the Québec government managed by Investissement Québec and Fonds Propres d’ Investissement Québec as well as current investors including Andes Growth, TB Pharma, Fonds de Solidarité FTQ, and CTI Life Sciences. “Québec’s life-sciences expertise is recognized worldwide. Our government is keen to support projects with the potential to generate meaningful spinoffs, like DalCor’s work on cardiovascular health,” said Pierre Fitzgibbon, Minister of Economy, Innovation and Energy, Minister Responsible for Regional Economic Development and Minister Responsible for the Montréal Region. “We are pleased to support DalCor in this round of financing so they can carry on development in precision medicine for cardiovascular disease,” said Guy LeBlanc, President, and CEO of Investissement Québec. “Their research can ultimately revolutionize their industry and reduce the number of cardiovascular events. Investissement Québec will keep supporting emerging young businesses to position Québec in key sectors of our economy, such as life sciences.”- - Notes: Dal-GenE-2: The primary objective of Dal-GenE-2 is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in 2,000 patients with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene. The trial is expected to start in Q3 2023 with an interim efficacy analysis in 2026, and completion anticipated in 2027. Dal-GenE: While the trial missed the primary endpoint, most likely due to the impact of the COVID-19 pandemic, the results show a 21% relative risk reduction (RRR) in fatal and non-fatal MI in 6,149 patients across 34 countries, and 45% RRR in 1,200 patients in North America. These data support the further development of dalcetrapib. DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients. DalCor Pharmaceuticals holds the worldwide exclusive license to develop, manufacture and commercialise dalcetrapib, and holds the right to the genetic marker for use with dalcetrapib in patients with the AA genotype at variant rs1967309 in the ADCY9 gene. A companion diagnostic test, developed in conjunction with Roche Diagnostics, identifies patients with the ADCY9 AA genotype who may potentially benefit from dalcetrapib treatment. For more information, visit www.dalcorpharma.com.

Phase 3License out/in

21 Jul 2022

·www.globenewswire.com

dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal

Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and AA genotype at variant rs1967309 in the ADCY9 gene.LONDON and MONTREAL, July 21, 2022 (GLOBE NEWSWIRE) -- DalCor Pharmaceuticals announced the results of the dal-GenE Phase 3 cardiovascular precision medicine outcomes trial with publication of ‘Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial’ in the European Heart Journal.1 The dal-GenE (DAL-301) trial was initiated to determine the ability of dalcetrapib to reduce cardiovascular (CV) morbidity and mortality in a population experiencing an acute coronary syndrome (ACS) within 1-3 months before randomization (N=6147) and identified as carrying the AA genotype at variant rs1967309 in the adenylate cyclase type 9 (ADCY9) gene, as determined by the cobas® ADCY9 genotype test. This AA genotype is carried by approximately 20% of the total population and up to 40% in people of African descent. Eligible patients were optimally treated for CV risk factors. The prespecified primary endpoint was time-to-first event for the composite of CV death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) or non-fatal stroke. In the dal-GenE trial, treatment with dalcetrapib in the intent-to-treat (ITT) analysis did not demonstrate a statistically significant result, with the composite primary endpoint event occurring in 9.5% of the patients in the dalcetrapib group, as compared with 10.6% in the placebo group (hazard ratio (HR) 0.88; 95% CI 0.75-1.03; p=0.12). However: On fatal and non-fatal MI, the dalcetrapib treatment showed a relative risk reduction of 21% compared to placebo (5.9% vs. 7.3%; HR 0.79; 95% CI 0.65-0.96; p=0.02). Dalcetrapib was safe and well tolerated in the dal-GenE trial.For the seven months prior to the COVID-19 pandemic, the hazard ratio and p-value in the dal- GenE trial were consistently clinically meaningful (HR< 0.85) and statistically significant (p<0.05).Study results censored on January 2020, prior to the COVID-19 pandemic, showed a relative risk reduction of 18% (HR = 0.82, 95% CI, 0.68-0.98; p=0.03) in the occurrence of the primary endpoint in the dalcetrapib treated group compared to placebo indicating that dalcetrapib appeared to be associated with this benefit up to the emergence of COVID-19.COVID-19 occurred as early as January 2020 worldwide and had a global impact on cardiovascular care. In particular, the numbers of patients diagnosed and hospitalized with myocardial infarction decreased steeply, while deaths increased. The dal-GenE study endpoints appear to have been impacted by the last 17 months of follow-up that occurred during COVID- 19 pandemic. The ratio of non-fatal events to death dropped from 1.7 to 0.9 during this period, most likely due to a reduction of reporting in non-fatal events and an increase in CV and non-CV death during the pandemic compared to pre-COVID. This finding is consistent with the published impact of the pandemic on cardiovascular care2.A pre-specified on-treatment sensitivity analysis of the primary endpoint showed a relative risk reduction of 17% with dalcetrapib treatment compared to placebo (7.8% vs. 9.3%; HR 0.83; 95% CI 0.70-0.98, p=0.03).Further pre-specified analyses demonstrated that patients at a higher risk had greater benefits on dalcetrapib treatment. In patients with type 2 diabetes, the observed relative risk reduction with dalcetrapib was 23% versus placebo (HR = 0.77; 95% CI, 0.60-0.99, p=0.04).In North America, where randomized patients were at a higher risk, they had a relative risk reduction of 41% in the primary composite endpoint (HR 0.59; 95% CI, 0.42-0.82, p=0.002). In contrast, countries with low-risk patients representing 20% of randomized patients had no significant benefit. Pre-COVID-19, the clinical efficacy of dalcetrapib seen in the dal-GenE study was also consistent with that of the retrospective analysis conducted in patients with the rs1967309 AA genotype in the dal-OUTCOMES study3. The totality of these data validates the pharmacogenetic hypothesis that dalcetrapib can safely improve, beyond the current standard of care, the prognosis of ACS patients with the rs1967309 AA genotype. DalCor is working closely with Health Authorities to determine the path forward for the approval of dalcetrapib for the treatment of patients with the rs1967309 AA genotype following an ACS event. About DalCorDalCor is a biopharmaceutical company with a focus on addressing cardiovascular disease, the greatest global healthcare burden. Our purpose is to deliver the first pharmacogenomic precision medicine in cardiovascular disease that specifically targets patients with the ADCY9 AA genotype. For more information, please visit dalcorpharma.com. About dal-GenEdal-GenE was a double-blind, parallel-group, placebo-controlled, randomized trial comparing orally administered dalcetrapib 600 mg once daily with placebo in a 1:1 ratio in patients with an acute coronary syndrome within 1 to 3 months and the AA genotype at variant rs1967309 in the ADCY9 gene. A total of 6147 patients were randomly assigned to receive dalcetrapib 600 mg or placebo daily. The primary endpoint was the time from randomization to first occurrence of cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, or non-fatal stroke. Participants were enrolled across 630 investigational sites located in North America, South America, Europe, Middle East, South Africa, Australia, and New Zealand. Patients were eligible if they were at least 45 years of age, recently hospitalized for an acute coronary syndrome within the previous 1 to 3 months, clinically stable, treated with guidelines-based management of LDL- cholesterol at a minimum to a target level less than 2.6 mmol/L, and confirmed in a central laboratory to have the AA genotype at variant rs1967309 in the ADCY9 gene. About DalcetrapibDalcetrapib is potentially the first pharmacogenomic precision medicine in cardiovascular disease developed for patients with the ADCY9 AA genotype. A companion diagnostic test, developed in conjunction with Roche Molecular Systems, identifies patients with the ADCY9 AA genotype who may potentially benefit from dalcetrapib treatment. DalCor obtained global rights to develop, manufacture and commercialize dalcetrapib under a license and collaboration agreement with Roche. References Tardif JC, Pfeffer MA, Kouz S, et al. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial. Eur Heart J 2022. European Heart Journal (2022) 00, 1–10 https://doi.org/10.1093/eurheartj/ehac374Nadarajah R, Wu J, Hurdus B, et al. The collateral damage of COVID-19 to cardiovascular services: a meta-analysis. European Heart Journal (2022) 00, 1–15 https://doi.org/10.1093/eurheartj/ehac227.Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089–2099. Media Contact:Clare EvansIris Communication+1 403 888 6869clare.evans@iriscommunication.net

Collaborate

100 Deals associated with Dalcetrapib

External Link

KEGG	Wiki	ATC	Drug Bank
D09708	Dalcetrapib	-	DB12181

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acrocallosal Syndrome	Phase 3	United States	DalCor Pharmaceuticals Canada, Inc.	01 Apr 2016
Acrocallosal Syndrome	Phase 3	United States	Roche Molecular Systems, Inc.	01 Apr 2016
Acrocallosal Syndrome	Phase 3	Argentina	DalCor Pharmaceuticals Canada, Inc.	01 Apr 2016
Acrocallosal Syndrome	Phase 3	Argentina	Roche Molecular Systems, Inc.	01 Apr 2016
Acrocallosal Syndrome	Phase 3	Australia	DalCor Pharmaceuticals Canada, Inc.	01 Apr 2016
Acrocallosal Syndrome	Phase 3	Australia	Roche Molecular Systems, Inc.	01 Apr 2016
Acrocallosal Syndrome	Phase 3	Austria	Roche Molecular Systems, Inc.	01 Apr 2016
Acrocallosal Syndrome	Phase 3	Austria	DalCor Pharmaceuticals Canada, Inc.	01 Apr 2016
Acrocallosal Syndrome	Phase 3	Belgium	DalCor Pharmaceuticals Canada, Inc.	01 Apr 2016
Acrocallosal Syndrome	Phase 3	Belgium	Roche Molecular Systems, Inc.	01 Apr 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04676867 (CTgov)	Phase 2	COVID-19	227	Placebo (Placebo Tablets)	pkghppxudc(sncxwkfxom) = vhufywjhqn bsmyjjdvej (vcbgzclvqk, dvcukjbkvc - jkongrvrun) View more	-	07 Dec 2022
				Dalcetrapib (900 mg Dose)	pkghppxudc(sncxwkfxom) = gfasdacyyq bsmyjjdvej (vcbgzclvqk, gwwiihsbcw - lrhphfzxdh) View more
NCT02525939 (dal-GenE, CTgov)	Phase 3	Acute Coronary Syndrome \| Acrocallosal Syndrome	6,147	Placebo (Placebo)	ncwsxjojpf = gxddafixxx yoywvrndix (clkqahesie, vrockifqvk - uzgumdykbn) View more	-	12 Oct 2022
				dalcetrapib (Dalcetrapib)	ncwsxjojpf = zuhwgmabgd yoywvrndix (clkqahesie, gszjbguppm - bzmoouefas) View more
NCT02525939 (dal-GenE, Pubmed \| Eur Heart J)	Phase 3	Acute Coronary Syndrome	6,147	Dalcetrapib 600mg	zhbadbcffw(fgoyolepvf): hazard ratio = 0.79 (95% CI, 0.65 - 0.96) View more	Negative	20 Jul 2022
				Placebo
NCT00658515 (dal-OUTCOMES, Pubmed \| Diabetes Care)	Phase 3	Coronary Disease	-	Dalcetrapib	qytlkzicli(studnovzvs) = uvkmvkkzwn evwenutgxk (frqenhscva )	Positive	01 May 2020
				Placebo	qytlkzicli(studnovzvs) = yehxmjohjj evwenutgxk (frqenhscva )
NCT01059682 (CTgov)	Phase 3	Morgellons Disease \| Coronary Artery Disease	936	Dalcetrapib (Dalcetrapib)	dqfdmdrovg(zzgagsoylz) = ckhmlrzivf oqynbtwopp (nmjkhetwnw, 3.69) View more	-	24 Mar 2020
				Placebo (Placebo)	dqfdmdrovg(zzgagsoylz) = oatgqwegts oqynbtwopp (nmjkhetwnw, 2.01) View more
NCT00353522 (CTgov)	Phase 2	Coronary Disease	135	dalcetrapib (Dalcetrapib)	dokkekmyeb(mwcicrayrr) = vjmvdijmjz qbjevolcox (cepqujlzzx, 1.17) View more	-	27 Jan 2020
				Placebo (Placebo)	dokkekmyeb(mwcicrayrr) = aaymivbbro qbjevolcox (cepqujlzzx, 1.49) View more
NCT00400439 (CTgov)	Phase 2	Coronary Disease	77	dalcetrapib (RO4607381) (Dalcetrapib (RO4607381))	xuqlqxebaz(qjnfbtaazn) = hrcaldwprh bjzefrpkxg (tjbdbkxbdu, 4.43) View more	-	03 Jan 2020
				placebo (Placebo)	xuqlqxebaz(qjnfbtaazn) = ahbpmsjrsh bjzefrpkxg (tjbdbkxbdu, 5.81) View more
NCT00655473 (CTgov)	Phase 2	Plaque, Atherosclerotic \| Coronary Disease	130	Dalcetrapib (RO4607381) (Dalcetrapib (RO4607381))	rfmvgqyrlc(uadeouykrk) = vlfbuzthgf atlrivwrtb (jqacarpimr, 3.018) View more	-	03 Jan 2020
				Placebo (Placebo)	rfmvgqyrlc(uadeouykrk) = tytebjvcwv atlrivwrtb (jqacarpimr, 3.111) View more
NCT00658515 (dal-OUTCOMES, CTgov)	Phase 3	Acute Coronary Syndrome \| Coronary Disease	15,871	Evidence-based medical care for Acute Coronary Syndrome+Dalcetrapib (RO4607381) (Dalcetrapib (RO4607381))	prqiyblsrg = ucmyzsfmbl rfeojeukbi (dmnhdkaobl, ijcwduofvh - hrowmznbzv) View more	-	03 Jan 2020
				Placebo (Placebo)	prqiyblsrg = opymgreeow rfeojeukbi (dmnhdkaobl, igsgjvekvq - tmgzvcddlo) View more
NCT00697203 (CTgov)	Phase 2	Dyslipidemias	292	Pravastatin+Dalcetrapib (Dalcetrapib 300mg)	nippcfhzbn(dsxodkrusm) = qawdufihrh zewzulmjki (lhvpzzpgfj, 2.19) View more	-	02 Jan 2020
				Pravastatin+Dalcetrapib (Dalcetrapib 600mg)	nippcfhzbn(dsxodkrusm) = lilyvnwqdq zewzulmjki (lhvpzzpgfj, 2.29) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis